Lupin Receives Approval For Bepotastine Tablets From CDSCO


Pharma major, Lupin Limited on Monday announced that it has received approval for Bepotastine Tablets from the Central Drugs Standard Control Organisation (CDSCO). Lupin will commence promoting the product in India shortly.

Bepotastine is a new second generation antihistamine medicine to be introduced into the Indian Pharmaceutical Market (IPM) which could benefit millions of patients suffering from allergic symptoms. It is a rapid-acting antihistamine that effectively controls day time and night time triggers of allergic symptoms.

Bepotastine is approved by PMDA Japan and is actively marketed in Japan and South East Asian countries.

The current market for plain antihistamines is estimated to be around Rs 860 crore growing at 14%. (IMS MAT March 2107)

The stock of Lupin Limited on the BSE is trading lower by 2.7% or Rs 35 per share at Rs 1279 per share at 1120 hours on Monday. The stock hit an intraday high of Rs 1326.50 per share and an intraday low of Rs 1277.55 per share.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717  
Share on Google Plus

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

0 comments: